Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours

Background: Somatostatin analogues (SSAs) are indicated to relieve carcinoid syndrome but seem to have antiproliferative effects on neuroendocrine tumours (NETs). This is the first prospective study investigating tumour stabilisation with the long-acting SSA lanreotide Autogel in patients with progr...

ver descrição completa

Detalhes bibliográficos
Autores: Martín-Richard, Marta|||0000-0003-4933-2463, Massutí, Bartomeu|||0000-0002-7608-3952, Pineda, Eva, Alonso Orduña, Vicente|||0000-0003-2280-1004, Marmol, Maribel, Castellano, Daniel|||0000-0002-9106-0687, Fonseca, Emilio, Galán, Antonio, Llanos, Marta, Sala, María Ángeles, Pericay, Carles|||0000-0002-4975-7851, Rivera, Fernando|||0000-0001-8915-226X, Sastre, Javier, Segura, Ángel, Quindós-Varela, María, Maisonobe, Pascal
Formato: artículo
Fecha de publicación:2013
País:España
Recursos:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:302940
Acesso em linha:https://ddd.uab.cat/record/302940
https://dx.doi.org/urn:doi:10.1186/1471-2407-13-427
Access Level:acceso abierto
Palavra-chave:Antiproliferative effect
Lanreotide autogel
Neuroendocrine tumours
Phase II clinical trial
Somatostatin analogues
id ES_6f84c79e44cd142fd1b6ccf65d78c101
oai_identifier_str oai:ddd.uab.cat:302940
network_acronym_str ES
network_name_str España
repository_id_str
spelling Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumoursA Spanish, multicentre, open-label, single arm phase II studyMartín-Richard, Marta|||0000-0003-4933-2463Massutí, Bartomeu|||0000-0002-7608-3952Pineda, EvaAlonso Orduña, Vicente|||0000-0003-2280-1004Marmol, MaribelCastellano, Daniel|||0000-0002-9106-0687Fonseca, EmilioGalán, AntonioLlanos, MartaSala, María ÁngelesPericay, Carles|||0000-0002-4975-7851Rivera, Fernando|||0000-0001-8915-226XSastre, JavierSegura, ÁngelQuindós-Varela, MaríaMaisonobe, PascalAntiproliferative effectLanreotide autogelNeuroendocrine tumoursPhase II clinical trialSomatostatin analoguesBackground: Somatostatin analogues (SSAs) are indicated to relieve carcinoid syndrome but seem to have antiproliferative effects on neuroendocrine tumours (NETs). This is the first prospective study investigating tumour stabilisation with the long-acting SSA lanreotide Autogel in patients with progressive NETs. Methods: This was a multicentre, open-label, phase II trial conducted in 17 Spanish specialist centres. Patients with well-differentiated NETs and radiologically confirmed progression within the previous 6 months received lanreotide Autogel, 120 mg every 28 days over ≤92 weeks. The primary endpoint was progression-free survival (PFS). Secondary endpoints were response rate, tumour biomarkers, symptom control, quality of life (QoL), and safety. Radiographic imaging was assessed by a blinded central radiologist. Results: Of 30 patients included in the efficacy and safety analyses, 40% had midgut tumours and 27% pancreatic tumours; 63% of tumours were functioning. Median PFS time was 12.9 (95% CI: 7.9, 16.5) months, and most patients achieved disease stabilisation (89%) or partial response (4%). No deterioration in QoL was observed. Nineteen patients (63%) experienced treatment-related adverse events, most frequently diarrhoea and asthenia; only one treatment-related adverse event (aerophagia) was severe. Conclusion: Lanreotide Autogel provided effective tumour stabilisation and PFS.Universitat Autònoma de Barcelona 22013-01-0120132013-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/302940https://dx.doi.org/urn:doi:10.1186/1471-2407-13-427reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:3029402026-06-06T12:50:31Z
dc.title.none.fl_str_mv Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours
A Spanish, multicentre, open-label, single arm phase II study
title Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours
spellingShingle Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours
Martín-Richard, Marta|||0000-0003-4933-2463
Antiproliferative effect
Lanreotide autogel
Neuroendocrine tumours
Phase II clinical trial
Somatostatin analogues
title_short Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours
title_full Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours
title_fullStr Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours
title_full_unstemmed Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours
title_sort Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours
dc.creator.none.fl_str_mv Martín-Richard, Marta|||0000-0003-4933-2463
Massutí, Bartomeu|||0000-0002-7608-3952
Pineda, Eva
Alonso Orduña, Vicente|||0000-0003-2280-1004
Marmol, Maribel
Castellano, Daniel|||0000-0002-9106-0687
Fonseca, Emilio
Galán, Antonio
Llanos, Marta
Sala, María Ángeles
Pericay, Carles|||0000-0002-4975-7851
Rivera, Fernando|||0000-0001-8915-226X
Sastre, Javier
Segura, Ángel
Quindós-Varela, María
Maisonobe, Pascal
author Martín-Richard, Marta|||0000-0003-4933-2463
author_facet Martín-Richard, Marta|||0000-0003-4933-2463
Massutí, Bartomeu|||0000-0002-7608-3952
Pineda, Eva
Alonso Orduña, Vicente|||0000-0003-2280-1004
Marmol, Maribel
Castellano, Daniel|||0000-0002-9106-0687
Fonseca, Emilio
Galán, Antonio
Llanos, Marta
Sala, María Ángeles
Pericay, Carles|||0000-0002-4975-7851
Rivera, Fernando|||0000-0001-8915-226X
Sastre, Javier
Segura, Ángel
Quindós-Varela, María
Maisonobe, Pascal
author_role author
author2 Massutí, Bartomeu|||0000-0002-7608-3952
Pineda, Eva
Alonso Orduña, Vicente|||0000-0003-2280-1004
Marmol, Maribel
Castellano, Daniel|||0000-0002-9106-0687
Fonseca, Emilio
Galán, Antonio
Llanos, Marta
Sala, María Ángeles
Pericay, Carles|||0000-0002-4975-7851
Rivera, Fernando|||0000-0001-8915-226X
Sastre, Javier
Segura, Ángel
Quindós-Varela, María
Maisonobe, Pascal
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Universitat Autònoma de Barcelona
dc.subject.none.fl_str_mv Antiproliferative effect
Lanreotide autogel
Neuroendocrine tumours
Phase II clinical trial
Somatostatin analogues
topic Antiproliferative effect
Lanreotide autogel
Neuroendocrine tumours
Phase II clinical trial
Somatostatin analogues
description Background: Somatostatin analogues (SSAs) are indicated to relieve carcinoid syndrome but seem to have antiproliferative effects on neuroendocrine tumours (NETs). This is the first prospective study investigating tumour stabilisation with the long-acting SSA lanreotide Autogel in patients with progressive NETs. Methods: This was a multicentre, open-label, phase II trial conducted in 17 Spanish specialist centres. Patients with well-differentiated NETs and radiologically confirmed progression within the previous 6 months received lanreotide Autogel, 120 mg every 28 days over ≤92 weeks. The primary endpoint was progression-free survival (PFS). Secondary endpoints were response rate, tumour biomarkers, symptom control, quality of life (QoL), and safety. Radiographic imaging was assessed by a blinded central radiologist. Results: Of 30 patients included in the efficacy and safety analyses, 40% had midgut tumours and 27% pancreatic tumours; 63% of tumours were functioning. Median PFS time was 12.9 (95% CI: 7.9, 16.5) months, and most patients achieved disease stabilisation (89%) or partial response (4%). No deterioration in QoL was observed. Nineteen patients (63%) experienced treatment-related adverse events, most frequently diarrhoea and asthenia; only one treatment-related adverse event (aerophagia) was severe. Conclusion: Lanreotide Autogel provided effective tumour stabilisation and PFS.
publishDate 2013
dc.date.none.fl_str_mv 2
2013-01-01
2013
2013-01-01
dc.type.none.fl_str_mv Article
http://purl.org/coar/resource_type/c_6501
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://ddd.uab.cat/record/302940
https://dx.doi.org/urn:doi:10.1186/1471-2407-13-427
url https://ddd.uab.cat/record/302940
https://dx.doi.org/urn:doi:10.1186/1471-2407-13-427
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Dipòsit Digital de Documents de la UAB
instname:Universitat Autònoma de Barcelona
instname_str Universitat Autònoma de Barcelona
reponame_str Dipòsit Digital de Documents de la UAB
collection Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869410501574787072
score 15,811543

Registos relacionados